NADAC acquisition cost data for ENBREL 50 MG/ML MINI CARTRIDGE. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
| 58406004404 | $1,596.93 | 2022-07-01 | Rx |
Generic: Etanercept | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $597.7M | 99,692 | 14,235 | $1,247.31 |
| 2020 | $583.4M | 90,789 | 12,573 | $1,318.14 |
| 2021 | $590.9M | 88,581 | 12,049 | $1,466.53 |
| 2022 | $612.0M | 85,310 | 11,311 | $1,630.34 |
| 2023 | $627.4M | 81,987 | 10,678 | $1,781.42 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $72.3M | 10,702 | 1,439 |
| New York | $47.7M | 5,788 | 846 |
| Texas | $45.7M | 5,906 | 792 |
| Florida | $36.9M | 4,549 | 662 |
| Michigan | $35.5M | 4,894 | 620 |
| Massachusetts | $24.5M | 3,159 | 384 |
| Pennsylvania | $23.5M | 3,064 | 393 |
| Illinois | $22.2M | 2,661 | 351 |
| New Jersey | $20.1M | 2,707 | 350 |
| Ohio | $20.1M | 2,479 | 348 |
| North Carolina | $18.2M | 2,350 | 290 |
| Washington | $17.0M | 2,148 | 309 |
| Puerto Rico | $15.8M | 2,241 | 270 |
| Georgia | $14.1M | 1,811 | 266 |
| Tennessee | $13.3M | 1,665 | 224 |
| Indiana | $12.0M | 1,534 | 201 |
| Virginia | $11.5M | 1,479 | 198 |
| Minnesota | $11.3M | 1,459 | 195 |
| Arizona | $10.9M | 1,387 | 195 |
| Kentucky | $10.7M | 1,454 | 203 |
| Wisconsin | $10.6M | 1,418 | 181 |
| Colorado | $9.9M | 1,474 | 185 |
| Connecticut | $9.3M | 1,108 | 161 |
| Missouri | $8.6M | 1,046 | 158 |
| Oregon | $8.1M | 1,082 | 153 |
| South Carolina | $7.6M | 851 | 144 |
| Alabama | $7.0M | 897 | 122 |
| Maryland | $6.8M | 811 | 125 |
| Arkansas | $5.9M | 754 | 102 |
| Louisiana | $5.9M | 798 | 109 |
| New Mexico | $5.8M | 757 | 100 |
| Oklahoma | $5.5M | 711 | 113 |
| Utah | $5.4M | 680 | 91 |
| Iowa | $5.2M | 704 | 85 |
| West Virginia | $4.0M | 603 | 75 |
| Mississippi | $3.9M | 488 | 73 |
| Maine | $3.8M | 480 | 65 |
| Nevada | $3.5M | 451 | 66 |
| New Hampshire | $3.0M | 346 | 46 |
| Idaho | $2.8M | 368 | 51 |
| Montana | $2.7M | 316 | 46 |
| Nebraska | $2.6M | 365 | 42 |
| Kansas | $2.5M | 308 | 49 |
| Alaska | $2.3M | 237 | 45 |
| Rhode Island | $2.2M | 302 | 41 |
| Delaware | $2.1M | 198 | 31 |
| Hawaii | $1.5M | 237 | 30 |
| Vermont | $1.3M | 164 | 21 |
| District of Columbia | $1.1M | 142 | 24 |
| South Dakota | $1.0M | 148 | 20 |
| North Dakota | $915.2K | 128 | 17 |
| Wyoming | $718.0K | 108 | 18 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.